Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology.

Di Giacomo AM, Covre A, Giacobini G, Ibrahim R, Lyman J, Natali PG, Maio M.

Cancer Immunol Immunother. 2019 Jan;68(1):143-150. doi: 10.1007/s00262-018-2286-x. Epub 2018 Dec 18. Review.

PMID:
30564888
2.

EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.

Capone E, Giansanti F, Ponziani S, Lamolinara A, Iezzi M, Cimini A, Angelucci F, Sorda R, Laurenzi V, Natali PG, Ippoliti R, Iacobelli S, Sala G.

Oncotarget. 2017 Sep 8;8(56):95412-95424. doi: 10.18632/oncotarget.20728. eCollection 2017 Nov 10.

3.

Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.

Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, Lamolinara A, Mirza H, Barcaroli D, Ermler S, Silva E, Yasaei H, Newbold RF, Vagnarelli P, Mottolese M, Natali PG, Perracchio L, Quist J, Grigoriadis A, Marra P, Tutt AN, Piantelli M, Iacobelli S, De Laurenzi V, Sala A.

J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29.

4.

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.

Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, Fratta E, Di Giacomo AM, Sigalotti L, Natali PG, Maio M.

Oncoimmunology. 2015 Apr 2;4(8):e1019978. eCollection 2015 Aug.

5.

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.

Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, Coral S, Sigalotti L.

Clin Cancer Res. 2015 Sep 15;21(18):4040-7. doi: 10.1158/1078-0432.CCR-14-2914.

6.

Prognostic relevance of LGALS3BP in human colorectal carcinoma.

Piccolo E, Tinari N, D'Addario D, Rossi C, Iacobelli V, La Sorda R, Lattanzio R, D'Egidio M, Di Risio A, Piantelli M, Natali PG, Iacobelli S.

J Transl Med. 2015 Jul 30;13:248. doi: 10.1186/s12967-015-0606-x.

7.

Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A.

Cancer Res. 2014 Dec 15;74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6.

8.

Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.

Lattanzio R, Ghasemi R, Brancati F, Sorda RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali PG, Piantelli M.

Oncogenesis. 2014 Sep 1;3:e118. doi: 10.1038/oncsis.2014.32.

9.

High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process.

Grassilli S, Brugnoli F, Lattanzio R, Rossi C, Perracchio L, Mottolese M, Marchisio M, Palomba M, Nika E, Natali PG, Piantelli M, Capitani S, Bertagnolo V.

Oncotarget. 2014 Jun 30;5(12):4320-36.

10.

The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A.

Carcinogenesis. 2014 Apr;35(4):840-8. doi: 10.1093/carcin/bgu018. Epub 2014 Jan 28.

11.

A melanoma immune response signature including Human Leukocyte Antigen-E.

Tremante E, Ginebri A, Lo Monaco E, Benassi B, Frascione P, Grammatico P, Cappellacci S, Catricalà C, Arcelli D, Natali PG, Di Filippo F, Mottolese M, Visca P, Benevolo M, Giacomini P.

Pigment Cell Melanoma Res. 2014 Jan;27(1):103-12. doi: 10.1111/pcmr.12164. Epub 2013 Oct 9.

PMID:
24011128
12.

Evaluation of MicroRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in northwestern Hungary.

Stánitz E, Juhász K, Tóth C, Gombos K, Natali PG, Ember I.

Anticancer Res. 2013 Aug;33(8):3195-200.

PMID:
23898078
13.

β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A.

Oncogene. 2013 Oct 17;32(42):5066-77. doi: 10.1038/onc.2012.527. Epub 2012 Dec 3.

PMID:
23208497
14.

LMNA knock-down affects differentiation and progression of human neuroblastoma cells.

Maresca G, Natoli M, Nardella M, Arisi I, Trisciuoglio D, Desideri M, Brandi R, D'Aguanno S, Nicotra MR, D'Onofrio M, Urbani A, Natali PG, Del Bufalo D, Felsani A, D'Agnano I.

PLoS One. 2012;7(9):e45513. doi: 10.1371/journal.pone.0045513. Epub 2012 Sep 26.

15.

Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, Bagnato A.

J Mol Med (Berl). 2013 Mar;91(3):395-405. doi: 10.1007/s00109-012-0956-2. Epub 2012 Sep 11.

PMID:
22965194
16.

Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.

Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto A, Perracchio L, Melucci E, Iacobelli S, Mottolese M, Natali PG, Piantelli M; CINBO (Consorzio Interuniversitario Nazionale per Bio-Oncologia).

Int J Cancer. 2013 Mar 1;132(5):1022-31. doi: 10.1002/ijc.27751. Epub 2012 Sep 1.

17.

Melanoma molecular classes and prognosis in the postgenomic era.

Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, Natali PG, Giacomini P.

Lancet Oncol. 2012 May;13(5):e205-11. doi: 10.1016/S1470-2045(12)70003-7. Review.

PMID:
22554548
18.

Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors.

Salvatori L, Caporuscio F, Verdina A, Starace G, Crispi S, Nicotra MR, Russo A, Calogero RA, Morgante E, Natali PG, Russo MA, Petrangeli E.

PLoS One. 2012;7(2):e31467. doi: 10.1371/journal.pone.0031467. Epub 2012 Feb 6.

19.

Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.

Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P.

Neoplasia. 2011 Sep;13(9):822-30.

20.

An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.

Sala G, Traini S, D'Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, Muraro R, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia.

Oncogene. 2012 Mar 8;31(10):1275-86. doi: 10.1038/onc.2011.322. Epub 2011 Aug 8.

PMID:
21822299
21.

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

Calabrò L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo AM, Danielli R, Cutaia O, Colizzi F, Covre A, Mutti L, Natali PG, Maio M.

J Cell Physiol. 2011 Oct;226(10):2595-600. doi: 10.1002/jcp.22600.

PMID:
21792917
22.

[Skin cancer risk factors in childhood: findings of a survey conducted within Italian areas with a different incidence of melanoma].

Ramazzotti V, Cercato MC, Terrenato I, Santi P, Falcini F, Assennato G, Gattei E, Catricalà C, Natali PG.

Epidemiol Prev. 2011 Mar-Apr;35(2):82-8. Italian.

PMID:
21628750
23.

Unknown primary tumors.

Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, Landriscina M, Zilli M, Natali PG, Tinari N, Iacobelli S.

Biochim Biophys Acta. 2011 Aug;1816(1):13-24. doi: 10.1016/j.bbcan.2011.02.002. Epub 2011 Mar 1. Review.

PMID:
21371531
24.

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.

Clin Cancer Res. 2011 Apr 15;17(8):2350-60. doi: 10.1158/1078-0432.CCR-10-2325. Epub 2011 Jan 10.

25.

The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2008-09.

Ablin RJ, Marincola FM, Natali PG.

J Transl Med. 2010 Oct 13;8:95. doi: 10.1186/1479-5876-8-95. No abstract available.

26.

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A.

J Immunother. 2010 Oct;33(8):810-6. doi: 10.1097/CJI.0b013e3181ee73a7.

PMID:
20842056
27.

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, Ferraresi V, Catricalà C, Belardelli F, Proietti E, Natali PG, Imberti L, Nisticò P.

Cancer Res. 2010 Sep 15;70(18):7084-92. doi: 10.1158/0008-5472.CAN-10-1326. Epub 2010 Sep 7.

28.

Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.

Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Aug;88(8):796-801. doi: 10.1139/Y10-052.

29.

Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.

Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Aug;88(8):782-7. doi: 10.1139/Y10-050.

30.

Skin cancer risk factors among primary school children: investigations in Western Hungary.

Fehér K, Cercato MC, Prantner I, Dombi Z, Burkali B, Paller J, Ramazzotti V, Sperduti I, Nádasi E, Parragi K, Menyhárt I, Natali PG, Ember I.

Prev Med. 2010 Sep-Oct;51(3-4):320-4. doi: 10.1016/j.ypmed.2010.07.002. Epub 2010 Jul 14.

PMID:
20637225
31.

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Jun;88(6):676-81. doi: 10.1139/Y10-053.

32.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241.

33.

In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor.

Kurzik-Dumke U, Hörner M, Nicotra MR, Koslowski M, Natali PG.

J Transl Med. 2010 Jun 17;8:58. doi: 10.1186/1479-5876-8-58.

34.

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F.

Breast Cancer Res. 2010;12(3):R27. doi: 10.1186/bcr2575. Epub 2010 May 12.

35.

NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.

Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D.

Cancer Res. 2010 Feb 1;70(3):916-24. doi: 10.1158/0008-5472.CAN-09-2582. Epub 2010 Jan 26. Erratum in: Cancer Res. 2010 Apr 1;70(7):2995.

36.

The "Excellence in Translational Medicine" and "Bedside-to-Bench" Awards 2007-08.

Ablin RJ, Marincola FM, Natali PG.

J Transl Med. 2009 Jul 9;7:57. doi: 10.1186/1479-5876-7-57. No abstract available.

37.

[Skin cancer risk factors in childhood: findings of a survey in an Italian area characterized by atypical migration].

Ramazzotti V, Terrenato I, Catricalà C, Pannozzo F, Natali M, Natali PG, Cercato MC.

Epidemiol Prev. 2009 Jan-Apr;33(1-2):45-50. Italian.

38.

From the fetal liver to spleen and gut: the highway to natural antibody.

Rosado MM, Aranburu A, Capolunghi F, Giorda E, Cascioli S, Cenci F, Petrini S, Miller E, Leanderson T, Bottazzo GF, Natali PG, Carsetti R.

Mucosal Immunol. 2009 Jul;2(4):351-61. doi: 10.1038/mi.2009.15. Epub 2009 May 6.

PMID:
19421184
39.

Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Serana F, Sottini A, Caimi L, Palermo B, Natali PG, Nisticò P, Imberti L.

J Transl Med. 2009 Mar 24;7:21. doi: 10.1186/1479-5876-7-21.

40.

Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A, Natali PG, Bagnato A.

Cancer Res. 2009 Mar 15;69(6):2669-76. doi: 10.1158/0008-5472.CAN-08-1879. Epub 2009 Mar 10.

41.

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11. doi: 10.1073/pnas.0807158106. Epub 2009 Feb 6.

42.

Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene.

Miccadei S, Pascucci B, Picardo M, Natali PG, Civitareale D.

J Exp Clin Cancer Res. 2008 Nov 18;27:71. doi: 10.1186/1756-9966-27-71.

43.

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, Aricò E, Valentini M, Bracci L, Cognetti F, Ciccarese M, Vercillo G, Roselli M, Fossile E, Tosti ME, Wang E, Marincola F, Imberti L, Catricalà C, Natali PG, Belardelli F, Proietti E.

Int J Cancer. 2009 Jan 1;124(1):130-9. doi: 10.1002/ijc.23886.

44.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.

45.

Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.

Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P.

Clin Cancer Res. 2008 Aug 1;14(15):4943-50. doi: 10.1158/1078-0432.CCR-08-0436.

46.

"Self and parent-assessed skin cancer risk factors in school-age children".

Cercato MC, Nagore E, Ramazzotti V, Guillén C, Terrenato I, Villena J, Lomuscio M, Natali PG, Schünemann HJ.

Prev Med. 2008 Jul;47(1):133-5. doi: 10.1016/j.ypmed.2008.03.004. Epub 2008 Mar 12.

PMID:
18420261
47.

Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues.

Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, van Endert P, Natali PG.

J Cell Physiol. 2008 Sep;216(3):742-9. doi: 10.1002/jcp.21454.

PMID:
18393273
48.

Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status.

Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M.

J Cell Physiol. 2008 May;215(2):287-91. doi: 10.1002/jcp.21380.

49.

Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor.

Kurzik-Dumke U, Hörner M, Czaja J, Nicotra MR, Simiantonaki N, Koslowski M, Natali PG.

Int J Mol Med. 2008 Jan;21(1):19-31.

PMID:
18097612
50.

Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing.

Benevolo M, Vocaturo A, Novelli F, Mariani L, Vocaturo G, Cianciulli AM, Marandino F, Perrone-Donnorso R, Giannarelli D, Natali PG, Mottolese M.

Anticancer Res. 2007 Jul-Aug;27(4C):2839-44.

Supplemental Content

Loading ...
Support Center